Under the terms of the collaboration, LabCorp will be Vanda's exclusive commercialization partner for tests for genetic markers of the Fanapta (TM) program. "Working with innovative companies like ...
BURLINGTON, N.C.--(BUSINESS WIRE)--LabCorp® (NYSE: LH) today announced a significant enhancement to its proprietary VistaSeq SM Hereditary Cancer portfolio, with ten new test panels focusing on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback